- Rapid Micro Biosystems ( NASDAQ: RPID ) expects to report total commercial revenue of $4.2M-$4.4M for the fourth quarter of 2022. Analysts estimate the life sciences technology company to generate $4.5M in revenue.
- For full year 2022, total commercial revenue is projected between $17M and $17.2M vs. $17.33M. The company placed nine new systems and completed the validation of 19 new systems during the year.
- Robert Spignesi, President and CEO, said, "We are pleased with our fourth quarter performance, which was in line with our expectations. As in-person customer interactions and commercial execution continue to improve, we are confident we will further capitalize on the market opportunity for the Growth Direct® system. We have the industry leading platform and a strong balance sheet to help us usher in our next chapter of robust, sustainable growth.
- Shares of Rapid Micro Biosystems ( RPID ) rose over ~4% shortly before 10.15 a.m. ET
For further details see:
Rapid Micro Biosystems sees Q4 revenue below estimates